‘Hy's law,’ the ‘Rezulin Rule,’ and other predictors of severe drug‐induced hepatotoxicity: putting risk‐benefit into perspective
- 30 January 2006
- journal article
- perspective
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 15 (4) , 221-229
Abstract
No abstract availableKeywords
This publication has 75 references indexed in Scilit:
- Hepatic Findings in Long-Term Clinical Trials of XimelagatranDrug Safety, 2005
- Human and animal hepatocytes in vitro with extrapolation in vivoChemico-Biological Interactions, 2004
- Expecting the Unexpected — Drug Safety, Pharmacovigilance, and the Prepared MindNew England Journal of Medicine, 2004
- Liver transplantation for acute liver failure from drug induced liver injury in the United StatesLiver Transplantation, 2004
- Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)The American Journal of Cardiology, 2003
- Acute liver failure associated with prolonged use of bromfenac leading to liver transplantationLiver Transplantation and Surgery, 1999
- Hepatotoxicity in drug development: detection, significance and solutionsJournal of Hepatology, 1997
- Criteria of drug-induced liver disordersJournal of Hepatology, 1990
- Ticrynafen-Associated Hepatic Injury: Analysis of 340 CasesHepatology, 1984
- Diphenylhydantoin sodium hepatitis1968